# Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer

> **NCT00400348** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Panzem Nanocrystal Colloidal Dispersion (NCD)

## Key facts

- **NCT ID:** NCT00400348
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-08
- **Final completion:** 2008-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2008-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400348, "Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00400348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*